NTLA
Intellia Therapeutics Inc
NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY
$13.48
+8.32% today
Updated 2026-04-30
Market cap
$1.48B
P/E ratio
—
P/S ratio
21.87x
EPS (TTM)
$-3.81
Dividend yield
—
52W range
$7 – $28
Volume
5.1M
Intellia Therapeutics Inc (NTLA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-428.90%
ROE
-53.50%
ROA
-27.10%
Debt/equity
0.13x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | $0.00 | $-14.31M | — | — | — |
| 2015 | $6.04M | $-12.40M | -84.81% | -221.86% | -205.11% |
| 2016 | $16.48M | $-31.63M | 100.00% | -195.15% | -191.97% |
| 2017 | $26.12M | $-67.54M | 100.00% | -266.32% | -258.62% |
| 2018 | $30.43M | $-85.34M | 100.00% | -298.58% | -280.42% |
| 2019 | $43.10M | $-99.53M | -151.52% | -246.78% | -230.92% |
| 2020 | $57.99M | $-125.57M | 100.00% | -235.51% | -216.52% |
| 2021 | $33.05M | $-259.72M | 100.00% | -810.37% | -785.76% |
| 2022 | $52.12M | $-474.19M | 85.47% | -879.04% | -909.78% |
| 2023 | $36.27M | $-481.19M | 75.26% | -1,420.51% | -1,326.51% |
| 2024 | $57.88M | $-519.02M | 82.23% | -923.10% | -896.77% |
| 2025 | $67.67M | $-412.69M | 76.47% | -651.67% | -609.85% |